JPRN-jRCT2080220594
Unknown
Phase 1
An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumors
Abbott Japan Co., Ltd.0 sitesAugust 22, 2008
Conditionssolid tumors
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- solid tumors
- Sponsor
- Abbott Japan Co., Ltd.
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects aged from 20 to 75 years at date of consent.
- •2\. Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase 1 mass balance study of [14C]TAS-205 in healthy volunteersDuchenne Muscular DystrophyJPRN-jRCT2071210008asermoaddeli Ali6
Withdrawn
Not Applicable
A phase I, open-label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy terminatioNA (healthy volunteers)10010273NL-OMON40897ObsEva SA6
Not yet recruiting
Phase 4
An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.Opioid-induced ConstipationOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12611000002987The Royal Children's Hospital6
Completed
Not Applicable
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered with Encorafenib and Binimetinib in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid TumorsNL-OMON55423Array BioPharma Inc. (a wholly ownd subsidairy of Pfizer Inc.)10
Active, not recruiting
Phase 1
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002985-28-BEMerck KGaA148